NCT05255406View on ClinicalTrials.gov

Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

PHASE2UnknownINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Non-Small-Cell Lung Cancer
Interventions
DRUG

Furmonertinib (160mg)

160mg/day orally on a continuous dosing schedule. If subjects suffer from AEs, they can get declined dosage (80mg).

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
collaborator

Allist Pharmaceuticals, Inc.

INDUSTRY

lead

Fudan University

OTHER

NCT05255406 - Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) | Biotech Hunter | Biotech Hunter